ArticleScientific data2017
A dataset quantifying polypharmacy in the United States.
Article in Scientific data, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Sterol pathway disruption in pregnancy: a link to autism.Molecular psychiatry · 2026Article
- Medications Associated with Increased Risk of Hypoglycemia in Older Adults on Sulfonylureas: A High-Throughput Case-Crossover-Based Screening Study.Drug safety · 2026Article
- Fall Outcomes in Older Adults Following Benzodiazepine/Z-Drug Discontinuation: A Retrospective Cohort Study in an Academic Health System.Drugs & aging · 2024Article
- Estimating the impact of physician risky-prescribing on the network structure underlying physician shared-patient relationships.Research square · 2024Article
- Estimating the impact of physician risky-prescribing on the network structure underlying physician shared-patient relationships.Applied network science · 2024Article
- Chronic Aripiprazole and Trazodone Polypharmacy Effects on Systemic and Brain Cholesterol Biosynthesis.Biomolecules · 2023Article
- Preferences for pharmacogenomic testing in polypharmacy patients: a discrete choice experiment.Personalized medicine · 2022Article
- Individual and simultaneous treatment with antipsychotic aripiprazole and antidepressant trazodone inhibit sterol biosynthesis in the adult brain.Journal of lipid research · 2022Article
- Comparing Effects of Polypharmacy on Inflammatory Profiles in Older Adults and Mice: Implications for Translational Aging Research.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Article
- Frailty and Determinants of Health Among Older Adults in the United States 2011-2016.Journal of aging and health · 2022Article
- Higher comorbidity burden is associated with lower self-reported quality of life after stroke.Frontiers in neurology · 2022Article
- Patients' attitudes toward deprescribing and their experiences communicating with clinicians and pharmacists.Therapeutic advances in drug safety · 2022Article
- Anti-DDI Resource: A Dataset for Potential Negative Reported Interaction Combinations to Improve Medical Research and Decision-Making.Journal of healthcare engineering · 2022Article
- An Atypical Case of Extreme Polypharmacy.Drug, healthcare and patient safety · 2022Article
- Quantifying the Severity of Adverse Drug Reactions Using Social Media: Network Analysis.Journal of medical Internet research · 2021Article
- Caffeic Acid on Metabolic Syndrome: A Review.Molecules (Basel, Switzerland) · 2021Review
- Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US).Advances in therapy · 2021Article
- Implementation of Pharmacogenomics and Artificial Intelligence Tools for Chronic Disease Management in Primary Care Setting.Journal of personalized medicine · 2021Article
- Polypharmacy Management in the Older Adults: A Scoping Review of Available Interventions.Frontiers in pharmacology · 2021Article
- Prevalence and Age Structure of Polypharmacy in Poland: Results of the Analysis of the National Real-World Database of 38 Million Citizens.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Polypharmacy is increasingly common in the United States, and contributes to the substantial burden of drug-related morbidity. Yet real-world polypharmacy patterns remain poorly characterized. We have counted the incidence of multi-drug combinations observed in four billion patient-months of outpatient prescription drug claims from 2007-2014 in the Truven Health MarketScan® Databases. Prescriptions are grouped into discrete windows of concomitant drug exposure, which are used to count exposure incidences for combinations of up to five drug ingredients or ATC drug classes. Among patients taking any prescription drug, half are exposed to two or more drugs, and 5% are exposed to 8 or more. The most common multi-drug combinations treat manifestations of metabolic syndrome. Patients are exposed to unique drug combinations in 10% of all exposure windows. Our analysis of multi-drug exposure incidences provides a detailed summary of polypharmacy in a large US cohort, which can prioritize common drug combinations for future safety and efficacy studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.